Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis

Glintborg B.; Sorensen J.; Hetland M. L.

首页> 外文期刊>Scandinavian journal of rheumatology >Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis

【24h】

Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis

机译：来自发起者的强制性非医用切换是否为生物纤维单雄兴奋剂导致门诊医疗资源的使用增加？炎症性关节炎患者的基于寄存器的研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Scandinavian journal of rheumatology》 |2018年第129期|共2页
作者
Glintborg B.; Sorensen J.; Hetland M. L.;
展开▼
作者单位

Copenhagen Univ Hosp Gentofte &

Herlev Hosp DANBIO Registry Glostrup Denmark;

Royal Coll Surgeons Ireland Healthcare Outcome Res Ctr Dublin Ireland;

Univ Copenhagen DANBIO Registry Copenhagen Denmark;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词

相似文献

外文文献

1. Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis [J] . Glintborg B., Sorensen J., Hetland M. L. Scandinavian journal of rheumatology . 2018,第Suppla129期

机译：来自发起者的强制性非医用切换是否为生物纤维单雄兴奋剂导致门诊医疗资源的使用增加？炎症性关节炎患者的基于寄存器的研究
2. Original article: Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis [J] . Bente Glintborg, Rikke Ibsen, Rebecca Elisabeth Qwist Bilbo, RMD Open . 2019,第2期

机译：原始文章：强制性的非医疗性从原始者转用仿制药依那西普是否会导致医疗保健使用和成本增加？基于丹麦注册的炎性关节炎患者研究
3. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry [J] . Glintborg Bente, Sorensen Inge Juul, Loft Anne Gitte, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2017,第8期

机译：来自发芽的全国性非医用开关到802例炎症性关节炎患者中的生物仿生CT-P13：DanBio注册处的1年临床结果
4. COMPARING STATISTICS WITH MACHINE LEARNING MODELS TO PREDICT DOSE INCREASE OF INFLIXIMAB FOR RHEUMATOID ARTHRITIS PATIENTS [C] . Stijn Van Looy, Bert Vander Cruyssen, Bart Wyns, IASTED International Conference on Artificial Intelligence and Soft Computing . 2005

机译：将统计数据与机器学习模型进行比较，以预测类风湿性关节炎患者英夫利昔单抗的剂量增加
5. A Cost-utility Analysis of Biosimilar Infliximab Compared to Reference Infliximab in Adult Switch Patients with Crohn's Disease: A Canadian Analysis [D] . Hughes, Avery. 2018

机译：生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者：加拿大分析
6. Original article: Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis [O] . Bente Glintborg, Jan Sørensen, Merete Lund Hetland 2018

机译：原始文章：从原发者向生物仿制药英夫利昔单抗的强制性非医疗转换是否会导致门诊医疗资源的更多使用？基于寄存器的炎性关节炎患者研究
7. Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis [O] . Bente Glintborg, Rikke Ibsen, Rebecca Elisabeth Qwist Bilbo, 2019

机译：来自发起者的强制性非医疗切换到生物仿制物entaneRept导致医疗保健使用和成本增加吗？基于丹麦寄存器的炎症性关节炎患者的研究

Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis

著录项

相似文献

相关主题

期刊订阅